26. HTLV-1-associated myelopathy Clinical trials / Disease details

Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000024086	2016/09/16	20/09/2016	Phase IIb clinical trial of steroid therapy in patients with HAM(Non progressor)	Phase IIb clinical trial of steroid therapy in patients with HAM(Non progressor) - HAMLET-P	HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)	Drugs which possibly affect assessment in the study (e.g. methylprednisolone, prednisolone and other agents targeted to HAM) will be forbidden or limited until Week 48 and periodic evaluation and tests will be performed.	St. Marianna University School of Medicine Hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	5	Phase 2	Japan
2	JPRN-UMIN000023798	2016/08/31	31/08/2016	Phase IIb clinical trial of steroid therapy in patients with HAM	Phase IIb clinical trial of steroid therapy in patients with HAM - HAMLET-P	HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)	Following to administrate Methylprednisolone 1000mg/day intravenously slowly for consecutive three days, Prednisolone is administered orally for a maximum dose in 0.5mg/kg/day, then decreased gradually and terminated. There is a case to maintain the dose of Prednisolone by the degree of a progress of underlying disease. Prednisolone is administered orally for a maximum dose in 0.5mg/kg/day, then decreased gradually and terminated. There is a case to maintain the dose of Prednisolone by the degree of a progress of underlying disease.	St. Marianna University School of Medicine Hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	8	Phase 2,3	Japan